Di Lorenzo R, Latella E, Gualtieri F, Adriani A, Ferri P, Filippini T
Healthcare (Basel). 2025; 13(3).
PMID: 39942433
PMC: 11816683.
DOI: 10.3390/healthcare13030244.
Mosandl C, Baltes-Fluckiger L, Kronschnabel J, Meyer M, Guessoum A, Herrmann O
Front Public Health. 2024; 12:1356988.
PMID: 38841675
PMC: 11151851.
DOI: 10.3389/fpubh.2024.1356988.
Nguyen T, Xiao E, Clark A, Shamim A, Maheshwari A
J Atten Disord. 2023; 28(1):51-57.
PMID: 37694675
PMC: 10676030.
DOI: 10.1177/10870547231197215.
Levine J, Swanson H
Case Rep Psychiatry. 2023; 2023:5574677.
PMID: 37609571
PMC: 10442178.
DOI: 10.1155/2023/5574677.
Vold J, Halmoy A, Chalabianloo F, Pierron M, Loberg E, Johansson K
BMC Psychiatry. 2023; 23(1):479.
PMID: 37386438
PMC: 10308780.
DOI: 10.1186/s12888-023-04980-w.
Is age of onset and duration of stimulant therapy for ADHD associated with cocaine, methamphetamine, and prescription stimulant misuse?.
McCabe S, Figueroa O, McCabe V, Schepis T, Schulenberg J, Veliz P
J Child Psychol Psychiatry. 2023; 65(1):100-111.
PMID: 37062713
PMC: 10852992.
DOI: 10.1111/jcpp.13807.
Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder.
Robinson C, Parker K, Kataria S, Downs E, Supra R, Kaye A
Health Psychol Res. 2022; 10(3):38360.
PMID: 36168642
PMC: 9501833.
DOI: 10.52965/001c.38360.
Co-occurring Mental Disorders in Transitional Aged Youth With Substance Use Disorders - A Narrative Review.
Kock P, Meyer M, Elsner J, Dursteler K, Vogel M, Walter M
Front Psychiatry. 2022; 13:827658.
PMID: 35280170
PMC: 8907594.
DOI: 10.3389/fpsyt.2022.827658.
Effects of family history of substance use disorder on reward processing in adolescents with and without attention-deficit/hyperactivity disorder.
Paraskevopoulou M, van Rooij D, Schene A, Batalla A, Chauvin R, Buitelaar J
Addict Biol. 2022; 27(2):e13137.
PMID: 35229951
PMC: 9285350.
DOI: 10.1111/adb.13137.
Effects of substance misuse on inhibitory control in patients with attention-deficit/hyperactivity disorder.
Paraskevopoulou M, van Rooij D, Schene A, Chauvin R, Buitelaar J, Schellekens A
Addict Biol. 2021; 27(1):e13063.
PMID: 34101312
PMC: 9285045.
DOI: 10.1111/adb.13063.
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.
Findling R, Candler S, Nasser A, Schwabe S, Yu C, Garcia-Olivares J
CNS Drugs. 2021; 35(6):643-653.
PMID: 34003459
PMC: 8219567.
DOI: 10.1007/s40263-021-00825-w.
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder.
Nasser A, Kosheleff A, Hull J, Liranso T, Qin P, Busse G
Int J Clin Pract. 2021; 75(8):e14330.
PMID: 33971070
PMC: 8365735.
DOI: 10.1111/ijcp.14330.
A Retrospective Comparative Study in Patients With Cocaine Use Disorder Comorbid With Attention Deficit Hyperactivity Disorder Undergoing an rTMS Protocol Treatment.
Cardullo S, Gomez Perez L, Cuppone D, Sarlo M, Cellini N, Terraneo A
Front Psychiatry. 2021; 12:659527.
PMID: 33841218
PMC: 8026860.
DOI: 10.3389/fpsyt.2021.659527.
Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults.
Faison S, Fry N, Adewole T, Odebo O, Wang Z, Maletic V
J Clin Psychopharmacol. 2021; 41(2):155-162.
PMID: 33587403
PMC: 7919699.
DOI: 10.1097/JCP.0000000000001361.
Effects of substance misuse on reward-processing in patients with attention-deficit/hyperactivity disorder.
Paraskevopoulou M, van Rooij D, Batalla A, Chauvin R, Luijten M, Schene A
Neuropsychopharmacology. 2020; 46(3):622-631.
PMID: 33184474
PMC: 8027205.
DOI: 10.1038/s41386-020-00896-1.
Alcohol and drug use disorders in adult attention-deficit/hyperactivity disorder: Prevalence and associations with attention-deficit/hyperactivity disorder symptom severity and emotional dysregulation.
Anker E, Haavik J, Heir T
World J Psychiatry. 2020; 10(9):202-211.
PMID: 33014721
PMC: 7515748.
DOI: 10.5498/wjp.v10.i9.202.
Effects of Substance Misuse and Family History of Substance Use Disorder on Delay Discounting in Adolescents and Young Adults with Attention-Deficit/Hyperactivity Disorder.
Paraskevopoulou M, van Rooij D, Schene A, Scheres A, Buitelaar J, Schellekens A
Eur Addict Res. 2020; 26(4-5):295-305.
PMID: 32659779
PMC: 7513619.
DOI: 10.1159/000509147.
Often Overlooked and Ignored, but Do Not Underestimate Its Relevance: ADHD in Addiction - Addiction in ADHD.
Schellekens A, van den Brink W, Kiefer F, Goudriaan A
Eur Addict Res. 2020; 26(4-5):169-172.
PMID: 32615559
PMC: 7949230.
DOI: 10.1159/000509267.
Psychiatric Comorbidities in Adult Attention-deficit/Hyperactivity Disorder: Prevalence and Patterns in the Routine Clinical Setting.
Ohnishi T, Kobayashi H, Yajima T, Koyama T, Noguchi K
Innov Clin Neurosci. 2020; 16(9-10):11-16.
PMID: 32082943
PMC: 7009330.
Treatment of Adult ADHD without Stimulants: Effectiveness in A Dually Diagnosed Correctional Population.
Bastiaens L, Scott O, Galus J
Psychiatr Q. 2018; 90(1):41-46.
PMID: 30255422
DOI: 10.1007/s11126-018-9602-7.